ADPT

Adaptive Biotechnologies Corporation NASDAQ

Healthcare ·Biotechnology ·US · adaptivebiotech.com

$14.50

Mkt Cap $2.2B

52w Low $8.38 49.5% of range 52w High $20.76

50d MA $14.34 200d MA $14.90

P/E (TTM) -36.6x

EV/EBITDA -89.6x

P/B 9.6x

Debt/Equity 1.3x

ROE -27.2%

P/FCF -50.3x

RSI (14) —

ATR (14) —

Beta 2.30

50d MA $14.34

200d MA $14.90

Avg Volume 2.0M

About

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past CO…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 5, 2026	AMC	-0.19	-0.09	+52.6%	16.47	+8.2%	-4.3%	-3.7%	-5.0%	-5.2%	-5.6%	—
Nov 5, 2025	AMC	-0.16	-0.15	+6.2%	17.59	-3.6%	-11.5%	-15.9%	-16.4%	-17.4%	-17.6%	—
Aug 5, 2025	AMC	-0.24	-0.17	+29.2%	11.05	+11.8%	+5.8%	+13.5%	+10.4%	+10.0%	+14.6%	—
May 1, 2025	AMC	-0.28	-0.20	+28.6%	7.36	+19.7%	+33.7%	+36.3%	+19.7%	+19.7%	+26.0%	—
Feb 11, 2025	AMC	-0.27	-0.23	+14.8%	7.80	-3.2%	-3.2%	+9.2%	+6.8%	+6.0%	+7.3%	—
Nov 7, 2024	AMC	-0.30	-0.22	+26.7%	5.63	+6.6%	+3.4%	+15.3%	+5.3%	+3.9%	-0.9%	—
Aug 1, 2024	AMC	-0.32	-0.26	+18.8%	4.45	-9.0%	-3.4%	-2.9%	+3.6%	-5.8%	-1.1%	—
May 7, 2024	AMC	-0.35	-0.33	+5.7%	3.11	+8.0%	+2.3%	+14.5%	+12.5%	+22.2%	+27.3%	—
Feb 14, 2024	AMC	-0.32	-0.30	+6.2%	3.94	-8.6%	+0.5%	-2.3%	-2.3%	-3.0%	-1.5%	—
Nov 9, 2023	AMC	-0.32	-0.35	-9.4%	4.29	-10.7%	-18.2%	-19.5%	-4.7%	-0.2%	-6.1%	—
Aug 2, 2023	AMC	-0.33	-0.33	+0.0%	7.96	-4.0%	-12.4%	-14.2%	-15.8%	-16.5%	-18.5%	—
May 3, 2023	AMC	-0.34	-0.40	-17.6%	7.50	-10.0%	-14.3%	-15.3%	-12.0%	-6.5%	-5.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 6	BTIG	Maintains	Buy → Buy	—	$16.47	$17.82	+8.2%	-4.3%	-3.7%	-5.0%	-5.2%	-5.6%
Feb 6	JP Morgan	Maintains	Overweight → Overweight	—	$16.47	$17.82	+8.2%	-4.3%	-3.7%	-5.0%	-5.2%	-5.6%
Jan 26	Guggenheim	Maintains	Buy → Buy	—	$18.55	$18.52	-0.2%	+3.1%	+3.7%	-0.3%	-1.0%	-0.3%
Nov 11	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$14.71	$14.65	-0.4%	-1.2%	-1.4%	-3.9%	-4.1%	-6.8%
Nov 6	BTIG	Maintains	Buy → Buy	—	$17.59	$16.95	-3.6%	-11.5%	-15.9%	-16.4%	-17.4%	-17.6%
Nov 6	JP Morgan	Maintains	Overweight → Overweight	—	$17.59	$16.95	-3.6%	-11.5%	-15.9%	-16.4%	-17.4%	-17.6%
Oct 22	BTIG	Maintains	Buy → Buy	—	$17.35	$17.02	-1.9%	-5.2%	-1.1%	-0.7%	-1.3%	-2.6%
Oct 15	Piper Sandler	Maintains	Overweight → Overweight	—	$15.58	$16.00	+2.7%	+9.8%	+10.8%	+4.6%	+14.4%	+11.4%
Oct 13	JP Morgan	Maintains	Overweight → Overweight	—	$15.17	$15.50	+2.2%	+2.2%	+2.7%	+12.8%	+13.8%	+7.4%
Aug 6	TD Cowen	Maintains	Buy → Buy	—	$11.05	$12.35	+11.8%	+5.8%	+13.5%	+10.4%	+10.0%	+14.6%
Aug 6	JP Morgan	Maintains	Overweight → Overweight	—	$11.05	$12.35	+11.8%	+5.8%	+13.5%	+10.4%	+10.0%	+14.6%
Aug 6	Piper Sandler	Maintains	Overweight → Overweight	—	$11.05	$12.35	+11.8%	+5.8%	+13.5%	+10.4%	+10.0%	+14.6%
May 6	Piper Sandler	Maintains	Overweight → Overweight	—	$10.03	$10.00	-0.3%	-12.2%	-12.2%	-7.6%	-10.0%	-5.2%
May 5	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$9.84	$9.80	-0.4%	+1.9%	-10.5%	-10.5%	-5.8%	-8.2%
May 2	Goldman Sachs	Maintains	Buy → Buy	—	$7.36	$8.81	+19.7%	+33.7%	+36.3%	+19.7%	+19.7%	+26.0%
Mar 21	Goldman Sachs	Upgrade	Neutral → Buy	—	$7.75	$8.05	+3.9%	+8.4%	+11.7%	+8.6%	+6.3%	+6.1%
Feb 20	Piper Sandler	Maintains	Overweight → Overweight	—	$8.37	$8.39	+0.2%	-0.5%	-1.2%	+0.6%	+0.6%	-0.1%
Feb 13	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$7.55	$7.65	+1.3%	+12.8%	+10.3%	+9.5%	+10.9%	+10.3%
Jan 28	Goldman Sachs	Maintains	Neutral → Neutral	—	$7.70	$7.73	+0.4%	+1.9%	+0.1%	+2.1%	+0.6%	+0.0%
Dec 18	BTIG	Maintains	Buy → Buy	—	$6.52	$6.63	+1.7%	-8.4%	-8.0%	-2.0%	-3.1%	-2.0%
Nov 11	Piper Sandler	Maintains	Overweight → Overweight	—	$5.82	$6.00	+3.1%	+11.5%	+1.9%	+0.5%	-4.1%	-12.7%
Oct 2	BTIG	Maintains	Buy → Buy	—	$5.02	$5.07	+1.0%	+2.4%	+0.8%	+10.0%	+7.8%	+4.6%
Aug 2	JP Morgan	Maintains	Overweight → Overweight	—	$4.45	$4.05	-9.0%	-3.4%	-2.9%	+3.6%	-5.8%	-1.1%
May 8	JP Morgan	Maintains	Overweight → Overweight	—	$3.11	$3.36	+8.0%	+2.3%	+14.5%	+12.5%	+22.2%	+27.3%
Apr 4	BTIG	Maintains	Buy → Buy	—	$2.68	$2.71	+1.1%	+1.9%	-3.7%	+5.6%	+9.3%	-0.4%
Feb 16	Goldman Sachs	Maintains	Neutral → Neutral	—	$3.96	$3.91	-1.3%	-2.8%	-2.8%	-3.5%	-2.0%	+2.0%
Feb 15	JP Morgan	Maintains	Overweight → Overweight	—	$3.94	$3.60	-8.6%	+0.5%	-2.3%	-2.3%	-3.0%	-1.5%
Nov 13	Piper Sandler	Maintains	Overweight → Overweight	—	$3.51	$3.42	-2.6%	-1.6%	+16.5%	+21.9%	+14.8%	+22.8%
Oct 24	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$4.18	$4.19	+0.2%	+12.2%	+2.4%	+6.3%	+1.7%	+3.6%
Oct 16	Piper Sandler	Maintains	Overweight → Overweight	—	$4.29	$4.24	-1.1%	+1.8%	+3.6%	-3.2%	-4.8%	-3.9%
Aug 8	Piper Sandler	Maintains	Overweight → Overweight	—	$6.70	$6.60	-1.5%	-0.7%	-3.1%	-4.2%	-6.0%	-6.6%
Aug 4	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$6.97	$7.19	+3.2%	-2.0%	-3.9%	-4.6%	-6.9%	-7.9%
May 5	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$6.43	$6.52	+1.4%	-1.2%	+2.6%	+9.0%	+10.7%	+5.6%
Feb 16	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$10.03	$9.91	-1.2%	-4.0%	-5.3%	-12.3%	-12.0%	-13.9%
Dec 21	Piper Sandler	Upgrade	Neutral → Overweight	—	$7.09	$7.82	+10.3%	+13.5%	+13.7%	+5.8%	+0.8%	-2.5%
Nov 7	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$8.89	$9.07	+2.0%	-14.7%	-12.5%	-18.4%	+1.9%	+5.1%
Oct 26	Piper Sandler	Maintains	Neutral → Neutral	—	$7.12	$7.03	-1.3%	+4.9%	+3.7%	+6.9%	+9.3%	+18.1%
Aug 17	Piper Sandler	Maintains	Neutral → Neutral	—	$11.90	$11.72	-1.5%	-2.9%	-6.1%	-11.5%	-12.7%	-9.7%
May 24	Goldman Sachs	Maintains	Neutral → Neutral	—	$7.90	$7.75	-1.9%	-5.4%	-4.7%	-4.2%	+4.1%	-1.0%
May 6	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$8.85	$8.69	-1.8%	-7.1%	-18.3%	-18.3%	-26.6%	-22.3%
Feb 16	BTIG	Maintains	Buy → Buy	—	$14.69	$14.54	-1.0%	+5.2%	-2.8%	-8.1%	-7.5%	-12.3%
Feb 15	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$14.67	$15.11	+3.0%	+0.1%	+5.3%	-2.7%	-8.0%	-7.4%
Aug 6	Goldman Sachs	Maintains	Neutral → Neutral	—	$37.69	$37.34	-0.9%	-6.3%	-6.8%	-8.8%	-13.3%	-13.6%
May 7	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$36.60	$36.53	-0.2%	-4.4%	-12.0%	-9.5%	-10.1%	-8.1%
Mar 3	Goldman Sachs	Downgrade	Buy → Neutral	—	$53.11	$52.89	-0.4%	-5.6%	-17.8%	-20.5%	-28.2%	-22.6%
Feb 26	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$55.31	$56.65	+2.4%	+2.3%	+4.7%	-4.0%	-9.3%	-21.0%
Nov 11	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$47.07	$49.01	+4.1%	+10.3%	+3.4%	+4.3%	-0.8%	-2.7%
May 19	Guggenheim	Maintains	Buy → Buy	—	$39.30	$39.89	+1.5%	+2.0%	+2.6%	+1.9%	+6.2%	+0.2%
Nov 4	Goldman Sachs	Downgrade	Buy → Neutral	—	—	—	—	—	—	—	—	—
Nov 3	Goldman Sachs	Downgrade	Buy → Neutral	—	—	—	—	—	—	—	—	—

Recent Filings

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

OraSure's stabilizing public health funding and near-term catalysts position it for revenue growth and margin expansion, making OSUR attractive for investors seeking profitability turnaround potential.

Mar 30

8-K

Adaptive Biotechnologies Corporation -- 8-K Filing

Adaptive Biotechnologies reported strong fourth quarter and full year 2025 financial results, with CEO Chad Robins highlighting outstanding execution and meaningful business progress.

Feb 5

Data updated apr 24, 2026 10:59am · Source: massive.com